New First-in-Class Treatment Fycompa® Launches in Denmark for Most Common Form of Epilpesy

New First-in-Class Treatment Fycompa® Launches in Denmark for Most Common Form of Epilpesy PR Newswire HATFIELD, England, September 18, 2012 HATFIELD, England, September 18, 2012 /PRNewswire/ -- ®Fycompa (perampanel), is launched today in Denmark as the first in an entirely new class of treatment for uncontrolled partial epilepsy (the most common form of the condition). The new therapy has demonstrated efficacy in partial onset seizures, in particular with secondary generalisations. It is indicated as an adjunctive treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and [1]older. Following the UK and Germany, Denmark is one of the first countries in Europe to launch Fycompa. Perampanel is the first and only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in [2]causing seizures. This mechanism of action is different to other, currently available AEDs. In addition, perampanel has the added benefit of convenient, [1]once-daily dosing at bedtime and, significantly, is the only new-generation partial epilepsy treatment approved to treat adolescents with epilepsy from launch. [3]There are approximately 46,000 people in Denmark living with epilepsy. The successful treatment of partial-onset seizures remains a significant challenge in some patients and the incidence of uncontrolled partial epilepsy remains high despite many AEDs.